Indivior Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $4.20B
- P/E (TTM)
- 12.2
- Dividend yield
- –
Earnings
Next report expected Oct 29, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 3, 2026 | Before market open | $343.00M | $0.98 | $1.15 |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 30, 2026 | Before market open | $317.00M | $0.69 | $0.96 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $358.00M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 30, 2025 | Before market open | $314.00M | $0.33 | $0.72 |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 31, 2025 | Before market open | $302.00M | $0.14 | $0.51 |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 24, 2025 | After market close | $266.00M | $0.38 | $0.41 |
Company guidance
Outlook given with results on Aug 3, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDA*non-GAAP | Revised FY 2026 Guidance | $700.00M to $740.00M | Raised |
| Non-GAAP Operating Expenses*non-GAAP | Revised FY 2026 Guidance | $430.00M to $450.00M | Maintained |
| Net Revenue | Revised FY 2026 Guidance | $1.30B to $1.37B | Raised |
| Total SUBLOCADE Net Revenue | Revised FY 2026 Guidance | $1.01B to $1.05B | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Indivior Pharmaceuticals filed with the SEC
Payment of Special Dividend Contingent upon
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Merger of Equals to Create a
Regulation FD disclosure · EX-99.1 to Form 8-K
Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q2 2026 Financial Results August 3,
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
VOTING AGREEMENT (this “ Agreement ”) is made and entered into as of August 1, 2026, by and between Supernus Pharmaceuticals, Inc., a Delaware corporation (“ Supernus ”) and the undersigned stockholder
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
VOTING AGREEMENT (this “ Agreement ”) is made and entered into as of August 1, 2026, by and between Indivior Pharmaceuticals, Inc., a Delaware corporation (“ Indivior ”) and the undersigned stockholder
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS
Material agreement · Regulation FD disclosure · EX-99.3 to Form 8-K
Indivior Announces $175 Million Accelerated Share Repurchase
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q1 2026 Financial Results April 30,
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Indivior, Powering Recovery, Renewing Hope. Exhibit 99.3
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering
Other events · EX-99.1 to Form 8-K
Indivior Announces Proposed Convertible Senior Notes Offering
Other events · EX-99.1 to Form 8-K
Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q4 and FY 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
2026 Indivior, Powering Recovery, Renewing Hope. Exhibit 99.3
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
The purpose of this Policy is to set out the circumstances under which Executive Officers of the Company will be required to repay or return certain Excess
Material agreement · New financial obligation · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99 to Form 8-K
THIS FIRST AMENDMENT TO NOTE PURCHASE AGREEMENT , dated as of January 21, 2026 (this “ Amendment ”), is made by
Material agreement · New financial obligation · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Indivior Announces Completion of Redomiciliation to the United States
Material agreement · New financial obligation · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Indivior Provides Full-Year 2026 Financial Guidance and Business Update
Regulation FD disclosure · EX-99.1 to Form 8-K
Investor Presentation January 8, 2026
Regulation FD disclosure · EX-99.2 to Form 8-K
Indivior Announces Inclusion in the S&P SmallCap 600® Index
Regulation FD disclosure · EX-99.1 to Form 8-K
Indivior Concludes Legacy U.S. Department of Justice Matter
Agreement terminated · Regulation FD disclosure · EX-99.1 to Form 8-K
(incorporated in the United Kingdom with registered number 09237894)
Regulation FD disclosure · EX-99.1 to Form 8-K
Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q3 2025 Results October 30, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Investor Presentation October 30, 2025
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation
Regulation FD disclosure · EX-99.1 to Form 8-K
Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q2 2025 Results July 31, 2025 Exhibit
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Investor Presentation July 31, 2025
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Indivior Announces Inclusion in the U.S. Russell 2000 ® and 3000 ® Indexes
Regulation FD disclosure · EX-99.1 to Form 8-K
Indivior Appoints Tony Kingsley to the Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED.
Executive or director change · Other events · EX-99.2 to Form 8-K
In consideration of the rights and obligations contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Indivior and the Purchasers hereto agree as follows:
Executive or director change · Other events · EX-99.3 to Form 8-K
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 Important
Regulation FD disclosure · EX-99.1 to Form 8-K
Result of Annual General Meeting (‘AGM’)
Executive or director change · Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Indivior Announces Results for the First Quarter Ended March 31, 2025; FY 2025 Guidance Unchanged
Results of operations · EX-99.1 to Form 8-K
Q1 2025 Results April 24, 2025 Exhibit
Results of operations · EX-99.2 to Form 8-K